Abstract: The subject of this invention are native forms of fucoidan polysaccharide, desulfated fucoidan and derivatives obtained by processing to the level of fucose-oligosaccarides containing preferentially, but not exclusively less than 20 monosaccaride fucose units alpha-linked by a glycosidic bond, with an average molecular weight of preferentially less than 3 kDa. The poly- and oligosaccarides that are described according to the invention are natural and safe, and are used as a dietary supplement for the use in prevention and treatment of pathologies associated with Noroviruses or Rotaviruses, Salmonella sp. or Pseudomonas aeruginosa or Campylobacter jejuni and other enteroviruses and enteric pathogens that cause bacterial gastroenteritis, as well as in the food production process. The invention also relates to a method for the desulfation and fragmentation of fucoidans to generate desulfated poly- or oligo-fucoses.

Abstract: The subject of this invention are native forms of fucoidan polysaccharide, desulfated fucoidan and derivatives obtained by processing to the level of fucose-oligosaccarides containing preferentially, but not exclusively less than 20 monosaccaride fucose units alpha-linked by a glycosidic bond, with an average molecular weight of preferentially less than 3 kDa. The poly- and oligosaccarides that are described according to the invention are natural and safe, and are used as a dietary supplement for the use in prevention and treatment of pathologies associated with Noroviruses or Rotaviruses, Salmonella sp. or Pseudomonas aeruginosa or Campylobacter jejuni and other enteroviruses and enteric pathogens that cause bacterial gastroenteritis, as well as in the food production process. The invention also relates to a method for the desulfation and fragmentation of fucoidans to generate desulfated poly- or oligo-fucoses.

Abstract: The invention refers to peptide variants of the tumor marker MUC1 and their application in antigenic and immunogenic remedies. It concretely refers to peptide variants of the MUC1 tandem repeat unit within the VNTR (=variable number of tandem repeats) domain.

Abstract: Embodiments of the invention provide tumour vaccines, especially for activation of glycopeptide-specific cytotoxic T-cells by MHC class I pathway, comprising at least one peptide of 8-11 amino acids derived from the region SAPDTRPAPGST of the human epithelial mucin MUC1 containing the immunodominant PDTRPAP region and which is glycosylated on threonine of the immunodominant PDTRPAP region and start with SAP, APD or PDT at it's N-terminus.

Abstract: Tumor vaccines for the use against MUC1 positive carcinomas are presented. A tumor vaccine containing synthetic peptides comprising sequences of the human epithelial mucin MUC1 containing the immunodominat region PDTRPAP which is glycosylated at the threonine. Preferred glycosylation of the immunodominant region is a O-glycosidically linked a-N-acetylgalactosamine (GalNAc) or short chained oligosaccharides. The present invention can be used on all MUC1-positive carcinomas.

Abstract: Provided are novel MUC1 peptides for use in anti-tumor vaccination and methods of producing those peptides. Furthermore, methods of producing a population of autologous antigen presenting cells (APCs) and of producing genetically engineered APCs, which are capable of inducing effective immune responses against MUC1 are described. The described peptides are particularly useful for the treatment of breast cancer or other MUC1-positive carcinomas including colorectal, pancreatic and gastric carcinomas.